Starting GLP-1: eligibility, contraindications, and baseline checks
Starting GLP-1: eligibility, contraindications, and baseline checks
A structured before-you-start page covering who typically uses GLP-1s for weight management, what needs prescriber review first, and what a serious support product should capture before day one.
People deciding whether to start semaglutide, tirzepatide, or liraglutide for weight management, plus caregivers and support teams preparing the first month.
- Who usually fits GLP-1 weight-management treatment and who needs more review first
- Which contraindications and caution situations should already be known before day one
- Which baseline GI, intake, and hydration patterns are worth capturing before appetite drops
- What a companion system should have ready before the first dose window starts
- Clarify the actual treatment goal: obesity management, overweight plus comorbidity, cardiometabolic risk reduction, or continuation after prior use.
- Ask explicitly about pregnancy plans, pancreatitis history, gallbladder disease, severe GI slowing, MEN2, or medullary thyroid carcinoma history.
- Record the user’s current bowel pattern, meal rhythm, protein intake, hydration level, and prior response to appetite suppression.
- Know how the first 8 to 24 weeks will be supported before the first injection happens.
What to check before the first dose
| Topic | Why it matters | What a support product should capture |
|---|---|---|
| Treatment fit | The goal changes how aggressive the first months should feel and what success means | Reason for starting, prior attempts, insurance or affordability constraints |
| Contraindications / caution flags | These shape whether the user should start at all and how fast escalation thresholds should trigger | Pregnancy plans, thyroid cancer/MEN2 history, pancreatitis, gallbladder issues, major GI history |
| Baseline GI pattern | Without it, new symptoms are harder to interpret | Current bowel pattern, reflux, bloating, nausea history, abdominal pain pattern |
| Baseline intake behavior | Many side effects become worse when protein and fluids already run low | Meal timing, typical protein sources, fluid intake, meal tolerance, prior supplement use |
Situations that need prescriber discussion before starting
| Situation | Why it changes the plan | Companion implication |
|---|---|---|
| Pregnancy / trying to conceive / breastfeeding | The labels and timing around use differ from a standard weight-loss journey | Do not frame this as a routine self-guided start |
| Pancreatitis, gallbladder disease, severe abdominal pain history | GI or upper-abdominal symptoms deserve faster escalation | Red-flag rules should trigger earlier and more clearly |
| Existing severe constipation, vomiting, or low intake | Starting from a fragile GI baseline raises early friction risk | More intensive day-one and step-up monitoring is warranted |
| Thyroid cancer / MEN2 history in the warning category | This is a label-level issue, not a lifestyle preference | Keep the user in clinician-led, not content-led, decision mode |
What starting fit really means
For users, the start decision often feels binary: am I going on the medication or not. In practice, the more useful question is whether the therapy fits this person, at this point, with this risk profile and this support environment.
The official labels and clinical guidance matter because they shape who should take the drug, who should avoid it, and who needs a more careful discussion before starting. A product that only talks about weight loss upside and ignores entry conditions is not doing serious support work.
Who needs extra prescriber review before a first dose
Certain issues should be surfaced before day one rather than after symptoms appear. Pregnancy and planned pregnancy, prior pancreatitis, gallbladder disease, severe GI disease, personal or family history of medullary thyroid carcinoma or MEN2, and interactions with existing medications all belong in the start conversation.
Even when these do not automatically rule out therapy, they change how confident the plan should feel, which symptoms should trigger escalation faster, and how a companion product should frame the first weeks.
- Pregnancy, trying to conceive, or breastfeeding
- Personal or family history tied to medullary thyroid carcinoma or MEN2
- Pancreatitis history, active gallbladder issues, or severe abdominal pain history
- Significant GI slowdown, chronic vomiting, or existing intake instability
What baseline data should exist before appetite drops
Users often discover too late that once appetite suppression begins, it becomes harder to remember what their normal intake, stool pattern, hydration level, and protein habits looked like before treatment. That makes baseline capture more useful than it sounds.
At minimum, a support system should know current weight trend, meal timing, protein comfort, bowel rhythm, hydration habits, prior supplement use, and whether the person already struggles with dizziness, reflux, or constipation before the first dose.
What support should already be in place
The start plan should include what happens if nausea shows up, how dose-escalation expectations will be set, what counts as a red flag, and where the user will go for urgent clarification. Without that structure, users often interpret the first rough week as proof that the therapy is wrong for them.
This is also where the companion layer becomes more than content. It becomes the place where baseline risk, symptom triage, and first-line behavior guidance are unified into one path.
Do I need labs before starting GLP-1 for weight loss?
Specific baseline labs and medical review are prescriber decisions, but from a support perspective the key principle is the same: do not start blind to existing GI history, intake issues, and risk factors that change how the first weeks should be managed.
If I already have constipation or reflux, can I still start?
Possibly, but that baseline matters because it changes the symptom plan. Existing GI friction should be captured before the drug is started so worsening patterns are interpreted correctly.
Is the first month mainly about motivation?
No. The first month is mainly about fit, tolerability, and clear response rules. Motivation matters less than having the right structure when symptoms or low intake start showing up.